The fit older adult with acute myeloid leukemia: clinical challenges to providing evidence-based frontline treatment

2.

Walter

RB

,

Othus

M

,

Borthakur

G

, et al.

Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment

.

J Clin Oncol

.

2011

;

29

(

33

):

4417

-

4423

.

3.

Sorror

ML

,

Storer

BE

,

Fathi

AT

, et al.

Development and validation of a novel acute myeloid leukemia-composite model to estimate risks of mortality

.

JAMA Oncol

.

2017

;

3

(

12

):

1675

-

1682

.

4.

Klepin

HD

,

Geiger

AM

,

Tooze

JA

, et al.

Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia

.

Blood

.

2013

;

121

(

21

):

4287

-

4294

.

5.

Min

G-J

,

Cho

B-S

,

Park

S-S

, et al.

Geriatric assessment predicts nonfatal toxicities and survival for intensively treated older adults with AML

.

Blood

.

2022

;

139

(

11

):

1646

-

1658

.

6.

Ferrara

F

,

Barosi

G

,

Venditti

A

, et al.

Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making

.

Leukemia

.

2013

;

27

(

5

):

997

-

999

.

7.

Little

RF

,

Othus

M

,

Assouline

S

, et al.

Umbrella trial in myeloid malignancies: the Myelomatch national clinical trials network precision medicine initiative [abstract]

.

Blood

.

2022

;

140

(

suppl 1

):

9057

-

9060

.

8.

Eisfeld

AK

,

Kohlschmidt

J

,

Mrózek

K

, et al.

Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of alliance studies

.

Leukemia

.

2018

;

32

(

6

):

1338

-

1348

.

9.

Heuser

M

.

Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?

.

Hematology

.

2016

;

2016

(

1

):

24

-

32

. 2016.

10.

Erba

HP

,

Montesinos

P

,

Kim

H-J

, et al.

Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial

.

Lancet

.

2023

;

401

(

10388

):

1571

-

1583

.

11.

DiNardo

CD

,

Jonas

BA

,

Pullarkat

V

, et al.

Azacitidine and venetoclax in previously untreated acute myeloid leukemia

.

N Engl J Med

.

2020

;

383

(

7

):

617

-

629

.

12.

Pratz

KW

,

Wei

AH

,

Pollyea

DA

, et al.

Management of neutropenia during venetoclax-based combination treatment in patients with newly diagnosed acute myeloid leukemia [abstract]

.

Blood

.

2019

;

134

(

suppl 1

):

3897

.

13.

Pratz

KW

,

Jonas

BA

,

Pullarkat

V

, et al.

Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia

.

Am J Hematol

.

2024

;

99

(

4

):

615

-

624

.

14.

Garcia

JS WO

,

Wolach

O

,

Vachhani

P

, et al.

Comparative effectiveness of venetoclax combinations vs other therapies among patients with newly diagnosed acute myeloid leukemia: results from the AML Real World Evidence (ARC) initiative [abstract]

.

Blood

.

2021

;

138

(

suppl 1

):

2328

.

15.

Cherry

E

,

Abbott

D

,

Amaya

M

, et al.

Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia

.

Blood Adv

.

2021

;

5

(

24

):

5565

-

5573

.

16.

Matthews

AH

,

Perl

AE

,

Luger

SM

, et al.

Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia

.

Blood Adv

.

2022

;

6

(

13

):

3997

-

4005

.

17.

DiNardo

CD

,

Tiong

IS

,

Quaglieri

A

, et al.

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

.

Blood

.

2020

;

135

(

11

):

791

-

803

.

18.

Döhner

H

,

Pratz

KW

,

DiNardo

CD

, et al.

ELN risk stratification is not predictive of outcomes for treatment-naïve patients with acute myeloid leukemia treated with venetoclax and azacitidine [abstract]

.

Blood

.

2022

;

140

(

suppl 1

):

1441

.

19.

Dohner

H

,

Pratz

KW

,

DiNardo

CD

, et al.

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine

.

Blood

.

2024

;

144

(

21

):

2211

-

2222

.

20.

Lachowiez

CA

,

Ravikumar

VI

,

Othman

J

, et al.

Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML

.

Blood

.

2024

;

144

(

26

):

2788

-

2792

.

21.

Appelbaum

JS

,

Wei

AH

,

Mandrekar

SJ

, et al.

Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts

.

Leukemia

.

2024

;

38

(

2

):

389

-

392

.

22.

Farag

SS

,

Maharry

K

,

Zhang

M-J

, et al.

Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission

.

Biol Blood Marrow Transplant

.

2011

;

17

(

12

):

1796

-

1803

.

23.

Ustun

C

,

Le-Rademacher

J

,

Wang

HL

, et al.

Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study

.

Leukemia

.

2019

;

33

(

11

):

2599

-

2609

.

24.

Bolaños-Meade

J

,

Hamadani

M

,

Wu

J

, et al.

Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis

.

N Engl J Med

.

2023

;

388

(

25

):

2338

-

2348

.

25.

Lübbert

M

,

Wijermans

PW

,

Kicinski

M

, et al.

10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial

.

Lancet Haematol

.

2023

;

10

(

11

):

e879

-

e889

.

26.

Ganzel

C

,

Sun

Z

,

Cripe

LD

, et al.

Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience

.

Am J Hematol

.

2018

;

93

(

8

):

1074

-

1081

.

27.

Short

NJ

,

Daver

N

,

Dinardo

CD

, et al.

Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML

.

J Clin Oncol

.

2024

;

42

(

13

):

1499

-

1508

.

28.

Lachowiez

C

,

Loghavi

S

,

Zeng

Z

, et al.

A phase Ib/II study of ivosidenib with venetoclax ± azacitidine in IDH1-mutated myeloid malignancies

.

Cancer Discov

.

2023

;

4

(

4

):

276

-

293

.

29.

Issa

GC

,

Cuglievan

B

,

DiNardo

CD

, et al.

Early results of the phase I/II study investigating the all-oral combination of the menin inhibitor revumenib (SNDX-5613) with decitabine/cedazuridine (ASTX727) and venetoclax in acute myeloid leukemia (SAVE) [abstract]

.

Blood

.

2023

;

142

(

suppl 1

):

58

.

30.

Chua

CC

,

Roberts

AW

,

Reynolds

J

, et al.

Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy

.

J Clin Oncol

.

2020

;

38

(

30

):

3506

-

3517

.

31.

Cluzeau

T

,

Sebert

M

,

Rahmé

R

, et al.

APR-246 combined with azacitidine (AZA) in TP53 mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). a phase 2 study by the Groupe Francophone Des Myélodysplasies (GFM) [abstract]

.

Blood

.

2019

;

134

(

suppl 1

):

677

.

32.

Daver

N

,

Vyas

P

,

Chao

M

, et al.

A phase 3, randomized, open-label study evaluating the safety and efficacy of magrolimab in combination with azacitidine in previously untreated patients with TP53-mutant acute myeloid leukemia [abstract]

.

Blood

.

2021

;

138

(

suppl 1

):

3426

.